The Big Case

‘Pharma Bro’ Martin Shkreli Heads to Trial

Will the biotech entrepreneur face a karmic reckoning over charges he defrauded hedge fund investors?

Martin Shkreli, former chief executive officer of Turing Pharmaceuticals AG, arrives at federal court in Brooklyn, N.Y., on July 14, 2016.
Photographer: Victor J. Blue/Bloomberg

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Paul Barrett

June 15, 2017 at 2:28 AM UTC

This article is for subscribers only.

This article is part of the June 19, 2017 issue of businessweek.

The Big Case takes a close look at must-know legal disputes involving business, finance, consumers, or regulation. This week: The U.S. Attorney’s Office for the Eastern District of New York vs. Martin Shkreli

Notorious for raising the price of a life-saving drug 5,000 percent, Shkreli faces a June 26 trial on charges that he defrauded investors in hedge funds he managed and misappropriated assets belonging to a drug company he started.